Page 17 - CUA 2020_Sexual Dysfunction and Transplant

2020 CUA Abstracts

References Methods: We performed a population-based study of men aged 66 years
1. Westaby D, Ogle SJ, Paradinas FJ, et al. Liver damage from long-term or older ± a history of prostate cancer that were newly treated with
methyltestosterone. Lancet 1977;2:262-3. https://doi.org/10.1016/ TRT (oral, injection, gel, and patches) between the years 2008 and 2015
S0140-6736(77)90949-7 in Ontario, Canada using the Ontario Drug Benefit database and the
2. Charles Osterberg E, Bernie AM, Ramasamy R. Risks of testosterone Canadian Institute for Health Information. Patient age, type of therapy,
replacement therapy in men. Indian J Urol 2014;30:2-7. https://doi. practitioner type, and laboratory value data were extracted. Proportional
org/10.4103/0970-1591.124197 data was evaluated using a chi-squared test.
Results: A total of 574 men (4% of the cohort) with a history of pros-
MP-11.15 tate cancer and 14 929 men without prostate cancer all over the age
of 65 received TRT between 2008 and 2015. A greater proportion of
A significant proportion of men with a history of prostate men with a history of prostate cancer had their prostate-specific antigen
cancer receiving testosterone therapy do not receive appropriate (PSA) checked (71%, n=410) within one year of testosterone prescrip-
prostate-specific antigen monitoring tion than the general population (67%, n=9540; p<0.001); however, this
Benjamin Shiff , Jason Scovell , Sarah McGriff , Premal Patel , Christopher rate remained inadequately low. Men with a history of prostate cancer
2
2
1
1
J.D. Wallis , Yonah Krakowsky , Ranjith Ramasamy 5 were more likely to be treated with TRT by a urologist compared to the
4
3
1 Urology, University of Manitoba, Winnipeg, MB, Canada; Baylor College general population: prostate cancer (56% family practitioner [FP]; 37%
2
of Medicine, Houston, TX, United States; Urology, Vanderbilt University urology; 7% endocrinology) vs. all other patients (77% FP; 17% urology;
3
Medical Centre, Nashville, TN, United States; Urology, University of 6% endocrinology; p<0.01). Urologists were more likely to check PSA
4
Toronto, Toronto, ON, Canada; Urology, University of Miami, Miami, levels (79%) in men with a history of prostate cancer on TRT than FPs
5
FL, United States and endocrinologists (68% and 69%; p=0.03).
Introduction: Health practitioners are hesitant to prescribe testoster- Conclusions: Only 70% of men who receive TRT with a history of prostate
one replacement therapy (TRT) for men with history of prostate cancer. cancer have their PSA checked. Although PSA screening has declined
Emerging data suggests that TRT is safe in men with treated prostate among general practitioners, appropriate education for testing PSA among
cancer. We characterized the prescription and laboratory monitoring pat- men diagnosed with prostate cancer is critical.
terns of patients with diagnosed prostate cancer receiving TRT in a North
American healthcare system.

S148 CUAJ • June 2020 • Volume 14, Issue 6(Suppl2)